Genetic background modifies the effects of type 2 cannabinoid receptor deficiency on bone mass and bone turnover

Antonia Sophocleous1, Aymen I Idris, Stuart H Ralston

  • 1Rheumatic Diseases Unit, Centre for Molecular Medicine, MRC Institute of Genetics and Molecular Medicine, Western General Hospital, University of Edinburgh, Edinburgh, EH4 2XU, UK.

Insights

Genetic background significantly impacts type 2 cannabinoid receptor (Cnr2) deficiency effects on bone. CD1 mice show altered bone turnover and mass, unlike C57BL/6 mice, highlighting strain-specific skeletal regulation.

Area of Science:

  • Bone biology and metabolism
  • Endocannabinoid system research
  • Genetics and skeletal health

Background:

  • Cannabinoid receptors (e.g., Cnr2) are implicated in bone metabolism.
  • Previous studies on Cnr1 deficiency showed genetic background influences skeletal outcomes.
  • Understanding Cnr2's role requires examining strain-specific effects.

Purpose of the Study:

  • To investigate the impact of genetic background on the skeletal phenotype of type 2 cannabinoid receptor (Cnr2) deficient mice.
  • To compare Cnr2 (-/-) mice on a CD1 background with previously studied Cnr2 (-/-) mice on a C57BL/6 background.

Main Methods:

  • Phenotypic analysis of Cnr2 (-/-) mice on a CD1 background.
  • Comparison with existing data from Cnr2 (-/-) mice on a C57BL/6 background.
  • Assessment of bone turnover, bone mass, and age-related changes in trabecular and cortical bone.

Main Results:

  • Young female Cnr2 (-/-) CD1 mice exhibited low bone turnover and high trabecular bone mass compared to WT.
  • Age-related bone loss in Cnr2 (-/-) CD1 mice was greater than WT due to reduced bone formation.
  • No significant skeletal phenotype differences were observed between Cnr2 (-/-) and WT male mice or in cortical bone of either gender.

Conclusions:

  • Genetic background significantly influences the skeletal effects of Cnr2 deficiency.
  • Cnr2 deficiency has site- and gender-specific impacts on bone, primarily affecting trabecular bone.
  • Further research into responsible pathways could elucidate cannabinoid receptor roles in bone metabolism.

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Bone Disorders01:29

Bone Disorders

Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Human Genetics01:28

Human Genetics

Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...